119 related articles for article (PubMed ID: 38740380)
21. Allogeneic hematopoietic stem cell transplantation for the treatment of chronic myeloid leukemia in the era of tyrosine kinase inhibitors.
Xu LP; Huang XJ
Chin Med J (Engl); 2013 Feb; 126(4):768-74. PubMed ID: 23422204
[No Abstract] [Full Text] [Related]
22. The new generation tyrosine kinase inhibitor improves the survival of chronic myeloid leukemia patients after allogeneic stem cell transplantation.
Shimazu Y; Murata M; Kondo T; Minami Y; Tachibana T; Doki N; Uchida N; Ozawa Y; Yano S; Fukuda T; Kato J; Ara T; Eto T; Ishikawa J; Nakamae H; Tanaka J; Ichinohe T; Atsuta Y; Nagamura-Inoue T;
Hematol Oncol; 2022 Aug; 40(3):442-456. PubMed ID: 35394658
[TBL] [Abstract][Full Text] [Related]
23. Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia.
Brissot E; Labopin M; Beckers MM; Socié G; Rambaldi A; Volin L; Finke J; Lenhoff S; Kröger N; Ossenkoppele GJ; Craddock CF; Yakoub-Agha I; Gürman G; Russell NH; Aljurf M; Potter MN; Nagler A; Ottmann O; Cornelissen JJ; Esteve J; Mohty M
Haematologica; 2015 Mar; 100(3):392-9. PubMed ID: 25527562
[TBL] [Abstract][Full Text] [Related]
24. Allogeneic Transplantation in Chronic Myeloid Leukemia and the Effect of Tyrosine Kinase Inhibitors on Survival: A Quasi-Experimental Study.
Özen M; Üstün C; Öztürk B; Topçuoğlu P; Arat M; Gündüz M; Atilla E; Bolat G; Arslan Ö; Demirer T; Akan H; İlhan O; Beksaç M; Gürman G; Özcan M
Turk J Haematol; 2017 Mar; 34(1):16-26. PubMed ID: 27094579
[TBL] [Abstract][Full Text] [Related]
25. Allogeneic stem cell transplantation for chronic myeloid leukemia resistant to tyrosine kinase inhibitors.
Champlin R; Jabbour E; Kebriaei P; Anderlini P; Andersson B; de Lima M
Clin Lymphoma Myeloma Leuk; 2011 Jun; 11 Suppl 1(Suppl 1):S96-100. PubMed ID: 22035758
[TBL] [Abstract][Full Text] [Related]
26. Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias.
Nicolini FE; Basak GW; Soverini S; Martinelli G; Mauro MJ; Müller MC; Hochhaus A; Chuah C; Dufva IH; Rege-Cambrin G; Saglio G; Michallet M; Labussière H; Morisset S; Hayette S; Etienne G; Olavarria E; Zhou W; Peter S; Apperley JF; Cortes J
Blood; 2011 Nov; 118(20):5697-700. PubMed ID: 21926354
[TBL] [Abstract][Full Text] [Related]
27. Allogeneic stem cell transplantation for children and adolescents/young adults with de novo blastic phase chronic myeloid leukemia in the tyrosine kinase inhibitor era.
Ishida H; Shimada H; Tanizawa A; Shimazu Y; Tachibana T; Doki N; Ara T; Matsuo Y; Nara M; Toubai T; Ino K; Nakamae H; Kato K; Kato K; Sato A; Hino M; Matsumoto K; Atsuta Y; Yasui M; Nagamura-Inoue T
Am J Hematol; 2023 Aug; 98(8):E200-E203. PubMed ID: 37170859
[TBL] [Abstract][Full Text] [Related]
28. Effect of graft sources on allogeneic hematopoietic stem cell transplantation outcome in adults with chronic myeloid leukemia in the era of tyrosine kinase inhibitors: a Japanese Society of Hematopoietic Cell Transplantation retrospective analysis.
Ohashi K; Nagamura-Inoue T; Nagamura F; Tojo A; Miyamura K; Mori T; Kurokawa M; Taniguchi S; Ishikawa J; Morishima Y; Atsuta Y; Sakamaki H
Int J Hematol; 2014 Sep; 100(3):296-306. PubMed ID: 25085253
[TBL] [Abstract][Full Text] [Related]
29. Imatinib Mesylate Versus Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Chronic Myelogenous Leukemia.
Zhang GF; Zhou M; Bao XB; Qiu HY; Li Z; Xue SL
Asian Pac J Cancer Prev; 2016; 17(9):4477-4481. PubMed ID: 27797264
[TBL] [Abstract][Full Text] [Related]
30. Phase 1/2 study of nilotinib prophylaxis after allogeneic stem cell transplantation in patients with advanced chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia.
Shimoni A; Volchek Y; Koren-Michowitz M; Varda-Bloom N; Somech R; Shem-Tov N; Yerushalmi R; Nagler A
Cancer; 2015 Mar; 121(6):863-71. PubMed ID: 25387866
[TBL] [Abstract][Full Text] [Related]
31. Hematopoietic cell transplantation for chronic myeloid leukemia in developing countries: perspectives from Latin America in the post-tyrosine kinase inhibitor era.
Pasquini MC
Hematology; 2012 Apr; 17 Suppl 1():S79-82. PubMed ID: 22507787
[TBL] [Abstract][Full Text] [Related]
32. Prognostic factors for outcomes of allogeneic stem cell transplantation in chronic phase chronic myeloid leukemia in the era of tyrosine kinase inhibitors.
Lee SE; Choi SY; Kim SH; Jang EJ; Bang JH; Byeun JY; Park JE; Jeon HR; Oh YJ; Yahng SA; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Kim HJ; Lee JW; Min WS; Park CW; Kim DW
Hematology; 2014 Mar; 19(2):63-72. PubMed ID: 23684143
[TBL] [Abstract][Full Text] [Related]
33. Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era.
Warlick E; Ahn KW; Pedersen TL; Artz A; de Lima M; Pulsipher M; Akpek G; Aljurf M; Cahn JY; Cairo M; Chen YB; Cooper B; Deol A; Giralt S; Gupta V; Khoury HJ; Kohrt H; Lazarus HM; Lewis I; Olsson R; Pidala J; Savani BN; Seftel M; Socié G; Tallman M; Ustun C; Vij R; Vindeløv L; Weisdorf D
Blood; 2012 Apr; 119(17):4083-90. PubMed ID: 22408257
[TBL] [Abstract][Full Text] [Related]
34. Improved outcome in patients with chronic myelogenous leukemia after allogeneic hematopoietic stem cell transplantation over the past 25 years: a single-center experience.
Boehm A; Walcherberger B; Sperr WR; Wöhrer S; Dieckmann K; Rosenmayr A; Pernicka E; Fischer G; Worel N; Mitterbauer G; Schwarzinger I; Mitterbauer M; Haas OA; Lechner K; Hinterberger W; Valent P; Greinix HT; Rabitsch W; Kalhs P
Biol Blood Marrow Transplant; 2011 Jan; 17(1):133-40. PubMed ID: 20601032
[TBL] [Abstract][Full Text] [Related]
35. Allogeneic transplantation: a therapeutic option for myelofibrosis, chronic myelomonocytic leukemia and Philadelphia-negative/BCR-ABL-negative chronic myelogenous leukemia.
Mittal P; Saliba RM; Giralt SA; Shahjahan M; Cohen AI; Karandish S; Onida F; Beran M; Champlin RE; de Lima M
Bone Marrow Transplant; 2004 May; 33(10):1005-9. PubMed ID: 15048141
[TBL] [Abstract][Full Text] [Related]
36. Comparable Outcomes of Pre- Versus Post-Tyrosine Kinase Inhibitor Era Treatment in Chronic Myeloid Leukemia: A Retrospective Cohort Study With Long-term Follow-up.
Tavakoli S; Khalaj F; Kasaeian A; Mousavi SA; Mousavian AH; Arabi F; Rad S; Rostami S; Barkhordar M; Biglari M; Mardani-Fard HA; Alemi H; Khavandgar N; Kamranzadeh Fumani H; Janbabai G; Mousavi SA; Ghavamzadeh A; Vaezi M
Cell Transplant; 2023; 32():9636897231163212. PubMed ID: 37013251
[TBL] [Abstract][Full Text] [Related]
37. Outcome of allogeneic SCT in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy.
Oyekunle A; Zander AR; Binder M; Ayuk F; Zabelina T; Christopeit M; Stübig T; Alchalby H; Schafhausen P; Lellek H; Wolschke C; Müller I; Bacher U; Kröger N
Ann Hematol; 2013 Apr; 92(4):487-96. PubMed ID: 23250623
[TBL] [Abstract][Full Text] [Related]
38. Reduced-intensity allogeneic hematopoietic stem cell transplantation combined with imatinib has comparable event-free survival and overall survival to long-term imatinib treatment in young patients with chronic myeloid leukemia.
Zhao Y; Wang J; Luo Y; Shi J; Zheng W; Tan Y; Cai Z; Huang H
Ann Hematol; 2017 Aug; 96(8):1353-1360. PubMed ID: 28624905
[TBL] [Abstract][Full Text] [Related]
39. The role of allogeneic stem cell transplantation for CML in the tyrosine kinase inhibitor era.
Cutler C; Antin JH
Curr Hematol Malig Rep; 2006 Sep; 1(3):160-7. PubMed ID: 20425347
[TBL] [Abstract][Full Text] [Related]
40. A comparison of long-term outcomes of donor lymphocyte infusions and tyrosine kinase inhibitors in patients with relapsed CML after allogeneic hematopoietic cell transplantation.
Shanavas M; Messner HA; Kamel-Reid S; Atenafu EG; Gupta V; Kuruvilla J; Kim DD; Uhm J; Lambie A; Ellis L; Lipton JH
Clin Lymphoma Myeloma Leuk; 2014 Feb; 14(1):87-92. PubMed ID: 24252361
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
